Key Points
- Major shareholder Jennifer Pritzker sold 250,000 shares of Alphatec on Nov. 24 at an average price of $20.62 for $5.155M, trimming her stake by 2.24% to 10,895,045 shares (≈$224.7M).
- Alphatec recently reported a quarterly EPS of $0.03 (beating estimates) and revenue of $196.5M, up 30.4% year-over-year, while the stock trades near its 12‑month high with a market cap of about $3.36B.
- Analysts have been raising targets and ratings (consensus "Moderate Buy" with an average target ~$22.00), and institutional ownership is high at roughly 66.35%, led by large holdings from Vanguard and others.
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) major shareholder Jennifer Pritzker sold 250,000 shares of Alphatec stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $20.62, for a total value of $5,155,000.00. Following the completion of the transaction, the insider owned 10,895,045 shares of the company's stock, valued at approximately $224,655,827.90. This represents a 2.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Alphatec Stock Up 3.5%
Alphatec stock opened at $22.59 on Thursday. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The stock has a market capitalization of $3.36 billion, a PE ratio of -19.99 and a beta of 1.17. The business has a 50 day simple moving average of $16.88 and a 200-day simple moving average of $14.38. Alphatec Holdings, Inc. has a 12 month low of $8.69 and a 12 month high of $22.66.
Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. Alphatec's revenue was up 30.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts have recently commented on the stock. Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, October 18th. Barclays lifted their price objective on Alphatec from $22.00 to $23.00 and gave the stock an "overweight" rating in a report on Monday, November 3rd. Canaccord Genuity Group increased their target price on Alphatec from $20.00 to $25.00 and gave the company a "buy" rating in a report on Friday, October 31st. Needham & Company LLC lifted their price target on Alphatec from $16.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. started coverage on Alphatec in a research note on Friday, October 24th. They issued an "overweight" rating and a $19.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Alphatec presently has a consensus rating of "Moderate Buy" and an average target price of $22.00.
View Our Latest Stock Analysis on ATEC
Institutional Investors Weigh In On Alphatec
Several hedge funds and other institutional investors have recently bought and sold shares of ATEC. Nuveen LLC acquired a new position in Alphatec in the 1st quarter valued at about $135,874,000. Vanguard Group Inc. increased its holdings in shares of Alphatec by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company's stock worth $99,091,000 after buying an additional 158,295 shares during the last quarter. American Century Companies Inc. raised its position in shares of Alphatec by 2.6% during the 3rd quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company's stock valued at $92,133,000 after buying an additional 159,330 shares during the period. Royal Bank of Canada lifted its holdings in Alphatec by 10.8% in the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company's stock valued at $35,773,000 after acquiring an additional 342,656 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Alphatec by 7.4% in the second quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company's stock worth $29,946,000 after acquiring an additional 185,297 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.
About Alphatec
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
